Article ; Online: High monocytic MDSC signature predicts multi-drug resistance and cancer relapse in non-Hodgkin lymphoma patients treated with R-CHOP.
2024 Volume 14, Page(s) 1303959
Abstract: Introduction: Non-Hodgkin Lymphoma (NHL) is a heterogeneous lymphoproliferative malignancy with B cell origin. Combinatorial treatment of rituximab, cyclophsphamide, hydroxydaunorubicin, oncovin, prednisone (R-CHOP) is the standard treatment regimen for ...
| Abstract | Introduction: Non-Hodgkin Lymphoma (NHL) is a heterogeneous lymphoproliferative malignancy with B cell origin. Combinatorial treatment of rituximab, cyclophsphamide, hydroxydaunorubicin, oncovin, prednisone (R-CHOP) is the standard treatment regimen for NHL, yielding a complete remission (CR) rate of 40-50%. Unfortunately, considerable patients undergo relapse after CR or initial treatment, resulting in poor clinical implications. Patient's response to chemotherapy varies widely from static disease to cancer recurrence and later is primarily associated with the development of multi-drug resistance (MDR). The immunosuppressive cells within the tumor microenvironment (TME) have become a crucial target for improving the therapy efficacy. However, a better understanding of their involvement is needed for distinctive response of NHL patients after receiving chemotherapy to design more effective front-line treatment algorithms based on reliable predictive biomarkers. Methods: Peripheral blood from 61 CD20 Results: We observed a strong positive correlation between elevated level of CD33 Conclusion: Our data suggests that screening patients for high titre of M-MDSCs might be considered as a new potential biomarker and treatment modality in overcoming chemo-resistance in NHL patients. |
|---|---|
| MeSH term(s) | Humans ; Animals ; Mice ; Myeloid-Derived Suppressor Cells/metabolism ; Rituximab/pharmacology ; Rituximab/therapeutic use ; Rituximab/metabolism ; Vincristine/pharmacology ; Vincristine/therapeutic use ; Interleukin-10/metabolism ; Prednisone/pharmacology ; Prednisone/therapeutic use ; Interleukin-6/metabolism ; Neoplasm Recurrence, Local/metabolism ; Lymphoma, Non-Hodgkin/drug therapy ; Lymphoma, Non-Hodgkin/metabolism ; Cyclophosphamide/pharmacology ; Cyclophosphamide/therapeutic use ; Doxorubicin/pharmacology ; Doxorubicin/therapeutic use ; Doxorubicin/metabolism ; Lymphoma/metabolism ; Biomarkers/metabolism ; Drug Resistance, Multiple ; Tumor Microenvironment/physiology |
| Chemical Substances | Rituximab (4F4X42SYQ6) ; Vincristine (5J49Q6B70F) ; Interleukin-10 (130068-27-8) ; Prednisone (VB0R961HZT) ; Interleukin-6 ; Cyclophosphamide (8N3DW7272P) ; Doxorubicin (80168379AG) ; Biomarkers |
| Language | English |
| Publishing date | 2024-01-18 |
| Publishing country | Switzerland |
| Document type | Journal Article ; Research Support, Non-U.S. Gov't |
| ZDB-ID | 2606827-8 |
| ISSN | 1664-3224 ; 1664-3224 |
| ISSN (online) | 1664-3224 |
| ISSN | 1664-3224 |
| DOI | 10.3389/fimmu.2023.1303959 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.